You are here: Home » Markets » News
Business Standard

Hikal hits new high on signing 10-year deal with global pharma Co

This contract entails the development and supply of a portfolio of niche APIs (Active Pharmaceutical Ingredient) over a period of 10 years

Hikal | Buzzing stocks | Markets

SI Reporter  |  Mumbai 

Hikal's R&D facility in Pune
Hikal's R&D facility in Pune

shares, on Wednesday, rallied 10 per cent to Rs 313.65, also its new high, on the BSE in intra-day trade after the company signed multi-year contract with a leading global pharmaceutical company.

In the past one month, the stock has zoomed 97 per cent, as compared to 3 per cent decline in the S&P BSE Sensex. Till 09:26 am, a combined 975,000 equity shares had changed hands on the NSE and BSE. There were pending buy orders for around 280,000 shares on these exchanges, data shows.

“This contract entails the development and supply of a portfolio of niche APIs (Active Pharmaceutical Ingredient) over a period of 10 years. The development will start this year and commercial supplies will commence post successful development and plant commercialisation estimated to be in FY2024 onwards,” said in a press release.

With this deal, is entering into a niche area of chemistry and products thereby bolstering its Animal Health vertical. Hikal and its customer will be jointly investing at its Panoli, Gujarat site to setup a multipurpose manufacturing asset for manufacturing of these API’s, it said.

The company’s management said Hikal and our customer will be partnering in setting up a manufacturing facility to maintain security of supplies for the next ten years. We are seeing multiple opportunities from several new and existing customers who are looking to diversify and de-risk their existing supply chain, the management said.

Hikal is a reliable long-term partner to companies in the pharmaceuticals, crop protection, and specialty chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, May 05 2021. 09:29 IST